Navigation Links
NanoLogix Inc. to Exhibit at The American Society for Microbiology (ASM) General Meeting in Philadelphia; Announces Two New Patents
Date:5/5/2009

HUBBARD, Ohio, May 5 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (Pink Sheets: NNLX) NanoLogix personnel will display the company's BNP(TM) rapid-detection technology at booth 749 during the 109th Annual ASM Meeting to be held at the Pennsylvania Convention Center in Philadelphia May 17th - 21st. The ASM meeting is the world's premier event for microbiology development. Representing NanoLogix will be Dr. Sergey Gazenko and CEO Bret Barnhizer. Exhibition information can be found at http://gm.asm.org/

NanoLogix recently received two patents. United States patent number 7,524,623 was granted for a "Method and device for rapid detection of microorganisms by changing the shape of micro-colonies" and is the first patent granted the company for BNC(TM) rapid-detection technology. Christopher Novak, NanoLogix Director of Intellectual Property said, "The issuance of the first US patent for the BioNanoChannel(TM) (BNC) this past week is a very significant development for NanoLogix. This patent provides NanoLogix with substantial intellectual property protection for their revolutionary rapid-detection technology. This greatly strengthens NanoLogix's patent portfolio with additional patents anticipated in the family of patent applications on file for this technology."

BNP(TM) and BNC(TM) are two distinct micro-biological rapid-detection technologies developed by NanoLogix. The BNP is a sandwiched-membrane, Petri-based system, that provides users the ability to view microorganism cultures up to four times faster than possible with traditional Petri techniques. The BNC is also a unique development in rapid detection. It utilizes disks the size of a quarter, each containing over two-million channels, to trap microorganisms for identification and culturing. Both BNP and BNC technologies offer the potential for reducing time-to-detection by significant amounts when contrasted with current methods in widespread use.

United States patent number 7,473,552 for the "Production of hydrogen gas and isolation of hydrogen producing microorganisms using replenishing coated substrates" was also recently received. The company adds this patent to their existing archived hydrogen-related research portfolio.

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in infectious and non-infectious human diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague. In addition to medical, Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation.

More information on NanoLogix is available at: www.nanologix.com

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

        Contact:
        NanoLogix, Inc.
        Investor Relations
        Carol Surrena
        Telephone: 330-534-0800
        E-mail: carol@nanologix.com


'/>"/>
SOURCE NanoLogix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
2. NanoLogix Inc. Announces Historical First in Energy Generation With Bioreactor-Produced Hydrogen at Welchs
3. NanoLogix Inc. to Present at EBW Expo & Conference 2007
4. NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update
5. NanoLogix, Inc. Makes Stock Pick List
6. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
7. National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welchs Foods
8. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
9. NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
10. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
11. NanoLogix Inc. Announces Joint Development With CL Solutions and First Sales of Rapid Detection Kits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , December 5, 2016 ... "Cell Expansion Market, by Products (Consumable, Instruments, Automated ... (Regenerative Medicine and Stem Cell Research, Cancer, and ... Institutes, Cell Banks) - Global Revenue, Trends, Growth, ... Scalar Market Research, the global cell expansion market ...
(Date:12/5/2016)... 2016 NxGen MDx announced today that it brought its NxGen ... we,ve been able to improve customer service through shortened turnaround times and ... Mack , CEO of NxGen MDx. ... , A decrease in turnaround times ... more job opportunities at the Grand Rapid headquarters. The NxGen ...
(Date:12/5/2016)... 5, 2016 The U.S. Biotechnology ... $108 billion of revenue and some $890 billion of ... on global biopharmaceuticals, and this figure is expected to ... lined up these four equities for assessment: Northwest Biotherapeutics ... (NASDAQ: ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
(Date:12/4/2016)... -- In five studies being presented today during the 58th ... in San Diego , researchers are ... of life-saving treatments to patients with a variety of ... therapies directly to the sites in the body where ... advantage over traditional, systemic methods. The studies highlight the ...
Breaking Biology Technology:
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
(Date:11/29/2016)... VILNIUS, Lithuania , Nov. 29, 2016 ... high-precision biometric identification and object recognition technologies, ... kit (SDK) for fingerprint recognition solutions that ... extract a fingerprint template using less than ... used in compact devices that have limited ...
Breaking Biology News(10 mins):